Recombinant Chicken AKR1B1L
| Cat.No. : | AKR1B1L-4515C |
| Product Overview : | Recombinant Chicken AKR1B1L full length or partial length protein was expressed. |
- Specification
- Gene Information
- Related Products
- Download
| Source : | Mammalian Cells |
| Species : | Chicken |
| Tag : | His |
| Form : | Liquid or lyophilized powder |
| Endotoxin : | < 1.0 eu per μg of the protein as determined by the LAL method. |
| Purity : | >80% |
| Notes : | This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications. |
| Storage : | Store it at +4 oC for short term. For long term storage, store it at -20 oC～-80 oC. |
| Storage Buffer : | PBS buffer |
| Gene Name : | AKR1B1L aldo-keto reductase family 1, member B1-like (aldose reductase) [ Gallus gallus (chicken) ] |
| Official Symbol : | AKR1B1L |
| Gene ID : | 418171 |
| Protein Refseq : | NP_001230519 |
| UniProt ID : | R4GG24 |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (16)
Ask a questionThe efficacy of AKR1B1L in the treatment of ocular diseases needs to be confirmed by further clinical studies.
Further clinical studies are needed to confirm the persistence of the therapeutic effect of recombinant AKR1B1L.
The efficacy and safety of recombinant AKR1B1L need to be further studied and confirmed, and it is not widely used in clinical therapy.
The efficacy of AKR1B1L needs to be further confirmed by clinical trials.
Currently, recombinant AKR1B1L has not been approved by the FDA for clinical use.
The effects of recombinant AKR1B1L versus other treatments still need to be studied and compared in clinical trials.
Recombinant AKR1B1L may have some side effects, such as nausea, diarrhea, headache, and allergic reactions may occur in some patients.
At present, the results of clinical trials on recombinant AKR1B1L are different, and some studies have shown that it has certain clinical effects in diabetes, ophthalmology and other fields, but it is not widely recognized.
Recombinant AKR1B1L can be used as a potential therapeutic target for cardiovascular disease, but further clinical studies are needed to confirm its efficacy and safety.
Recombinant AKR1B1L can effectively reduce the metabolites of glucose, so as to prevent or delay the damage of the eyes, kidneys, nerves and other organs caused by diabetes.
Compared with traditional treatment methods, recombinant AKR1B1L has a more specific target and can effectively reduce glucose metabolites, thereby preventing or delaying organ damage caused by diseases such as diabetes.
Recombinant AKR1B1L is usually administered by injection.
The safety of recombinant AKR1B1L has certain risks, such as the possibility of some side effects and allergic reactions in individual patients.
The dosage of recombinant AKR1B1L needs to be adjusted individually according to the specific situation of the patient, and is generally determined by the doctor according to the comprehensive consideration of the patient's physical condition and clinical manifestations.
Recombinant AKR1B1L is a synthetic enzyme prepared by genetic engineering technology that converts glucose into sorbitol.
Recombinant AKR1B1L is mainly used in the treatment of diabetes, eye diseases and cardiovascular diseases.
Customer Reviews (4)
Write a reviewAKR1B1L has good DNA binding ability and performs well in related experiments.
AKR1B1L has made significant research progress in the application of related fields.
Low immunogenicity and does not cause abnormal immune responses.
The structural integrity of AKR1B1L was verified, and the folding state and secondary structure were consistent with the native protein.
Ask a Question for All AKR1B1L Products
Required fields are marked with *
My Review for All AKR1B1L Products
Required fields are marked with *
Inquiry Basket
